中国药物警戒 ›› 2018, Vol. 15 ›› Issue (12): 761-763.
周秋云, 张宇, 张亮, 陆磊, 鲁涛
收稿日期:
2019-01-18
修回日期:
2019-01-18
出版日期:
2018-12-20
发布日期:
2019-01-18
作者简介:
周秋云,女,本科 ,副主任药师,临床药学。
基金资助:
ZHOU Qiuyun, ZHANG Yu, ZHANG Liang, LU Lei, LU Tao
Received:
2019-01-18
Revised:
2019-01-18
Online:
2018-12-20
Published:
2019-01-18
中图分类号:
周秋云, 张宇, 张亮, 陆磊, 鲁涛. 伊立替康注射液致UGT1A1*28野生型患者重度骨髓抑制和腹泻1例[J]. 中国药物警戒, 2018, 15(12): 761-763.
ZHOU Qiuyun, ZHANG Yu, ZHANG Liang, LU Lei, LU Tao. One Case of Severe Myelosuppression and Diarrhea Induced by Irinotecan Injection in a UGT1A1*28 Wide-type Patient[J]. Chinese Journal of Pharmacovigilance, 2018, 15(12): 761-763.
[1] Zhou C F, Ma T, Su Y, et al.UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastroin-testinal cancer[J]. Anticancer Agents Med Chem, 2013, 13(2): 235-241. [2] Zhang X G, Zhang X.Study on the development of the mechanism of action, prevention and treatment for irinotecan-induced diarrhea[J]. Chinese Journal of Pharmacovigilance, 2012, 9(9): 535-538. [3] Di Paolo A, Bocci G, Polillo M,et al.Pharmacokinetic and pharmacogenetic predictive markers of irinotecan activity and toxicity[J]. Curr Drug Metab, 2011, 12(10):932-943. [4] Innocenti F, Undevia S D, Iyer L, et al.Genetic variants in the UDP–glucuronosyltransferase 1A1 gene predict the risk of severe neu-tropenia of irinotecan[J]. J Clin Oncol, 2004, 22(8): 1382-1388. [5] Massacesi C, Terrazzino S, Marcucci F, et al.Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy[J]. Cancer, 2006, 106( 5): 1007-1016. [6] Liu X L, Yang M D, Gao J.Relationship between UGT1A1 gene pol-ymorphisms and toxicity of irinotecan[J]. Chin Remedies&Clin, 2013, 13( 11): 1402-1404. [7] Takahara N, Nakai Y, Isayama H, et al.Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer[J]. Cancer Chem Pharmacol, 2013, 71(1): 85-92. [8] Harada T, Saito H, Karino F, et al.Clinical usefulness of testing for UDP glucuronosyltransferase 1 family,polypeptide A1 polymorp-hism prior to the nititation of irinotecan-based chemotherapy[J]. Mol Clin Oncol, 2014, 2(5): 737-743. [9] Schulz C, Heinemann V, Schalhorn A, et al.UGT1A1 gene polymorphism Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorecatal cancer[J]. World J Gastroenterol, 2009, 15(40): 5058-5066. [10] Kehrer D, Sparreboom A, Verweijj, et al. Modualtion of irinotecan induced diarrhea by cotreatment with neomycin in cancer patients[J]. Clin Cancer Res, 2001, 7(5), 1136-1141. [11] 刘建平,邢建民. 循证的药品不良反应评价方法[J]. 中国药物警戒, 2010, 17(1): 12-15. [12] 范燕,汤韧,井春梅,等. 药学期刊药品不良反应案例报道论文的要点探讨[J].中国药物警戒, 2017, 1(2): 101-103. [13] Cheng L, Li M,Hu J, et al.UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analrsis in Asians[J]. Cancer Chemother Pharmaco, 2014, 73(3), 5551-560l. [14] Takano M, Kato M, Yoshikawa T, et al.Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination-chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study[J]. Oncology, 2009, 76(5): 315-321. [15] Han J Y, Lim H S, Sin E S, et al.Influence of the organican iontransporting polypeptide 1B1(OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advancednon-small cell lung cancer[J], Lung Cancer, 2008, 59(1): 69-75. [16] 张晓光,张侠. 25例伊立替康治疗晚期肠癌致不良反应的分析[J]. 中国药物警戒 , 2013, 10(3): 168-171. [17] Nies A T, Niemi M, burk O, et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of QATP1B3 and OATP2B1[J]. Genome Med, 2013, 5(1):1. [18] Takane H, Miyata M, Burioka N, et al.Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLO1B1*15 Allele[J]. Ther Drug Monit, 2007, 29(5): 666-668. |
[1] | 孙绮悦, 赵荣华, 郭姗姗, 包蕾, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 羚羊感冒口服液多重药理作用研究[J]. 中国药物警戒, 2024, 21(2): 127-131. |
[2] | 赵荣华, 孙静, 包蕾, 耿子涵, 陶夏莉, 张敬升, 庞博, 徐英莉, 曹姗, 李舒冉, 郭姗姗, 王道涵, 崔晓兰. 基于免疫调节探讨葛根汤颗粒治疗小鼠病毒性肺炎的作用机制[J]. 中国药物警戒, 2024, 21(2): 132-136. |
[3] | 包蕾, 耿子涵, 李舒冉, 冀祖恩, 赵荣华, 孙静, 郭姗姗, 崔晓兰. 瞬时受体电位通道在病毒性肺炎发展过程中的关键作用[J]. 中国药物警戒, 2024, 21(2): 137-140. |
[4] | 贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166. |
[5] | 李嘉昕, 刘慧敏, 钱文秀, 马宁, 宋丽丽, 李遇伯. 基于中药系统毒理学数据库的中药致肾毒性及药物规律研究[J]. 中国药物警戒, 2024, 21(2): 173-180. |
[6] | 范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184. |
[7] | 张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189. |
[8] | 王珊, 谢波, 刘慧敏, 李志浩. 基于FAERS数据库对塞来昔布不良事件信号的分析[J]. 中国药物警戒, 2024, 21(2): 190-194. |
[9] | 李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198. |
[10] | 徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203. |
[11] | 郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207. |
[12] | 方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210. |
[13] | 李娜, 郭军, 郭文佳, 吕茵茵, 李彩宏, 牟向东. 奥马珠单抗注射剂治疗哮喘致迟发型皮肤过敏反应1 例分析[J]. 中国药物警戒, 2024, 21(2): 211-212. |
[14] | 曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218. |
[15] | 朱盈, 沈璐, 李岚, 吴建民, 高晓洁. 新法规体系下我国牙膏不良反应监测工作分析与思考[J]. 中国药物警戒, 2024, 21(2): 219-222. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||